Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
Impact Biomedical (IBO) has secured U.S. patent No. 12,357,584 B2 for its 3F™ technology platform, focusing on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
The technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77%. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
Impact Biomedical (IBO) ha ottenuto il brevetto statunitense n. 12.357.584 B2 per la sua piattaforma tecnologica 3F™, incentrata sul controllo delle malattie infettive tramite fragranze funzionali di origine vegetale. Il brevetto, valido fino a dicembre 2038, copre composizioni esclusive con proprietà antimicrobiche e antivirali efficaci contro diversi agenti patogeni, tra cui E. coli, MRSA, influenza, rinovirus e M. tuberculosis.
La tecnologia risponde alla crescente domanda nel mercato delle malattie infettive, previsto in espansione da $21.7B nel 2024 a $34B nel 2023, con un CAGR del 5,77%. L'azienda sta attivamente cercando partnership per commercializzare la tecnologia 3F™ negli Stati Uniti e a livello globale.
Impact Biomedical (IBO) ha obtenido la patente estadounidense No. 12,357,584 B2 para su plataforma tecnológica 3F™, centrada en controlar las enfermedades infecciosas mediante fragancias funcionales de origen vegetal. La patente, válida hasta diciembre de 2038, cubre composiciones únicas con propiedades antimicrobianas y antivirales eficaces frente a diversos patógenos, incluidos E. coli, MRSA, influenza, rinovirus y M. tuberculosis.
La tecnología responde al creciente mercado de enfermedades infecciosas, proyectado a expandirse de $21.7B en 2024 a $34B en 2023, con una TCCA del 5,77%. La compañía está activamente buscando asociaciones para comercializar la tecnología 3F™ en EE. UU. y a nivel mundial.
임팩트 바이오메디컬(Impact Biomedical, IBO)은 식물 유래 기능성 향을 통한 감염병 제어에 중점을 둔 3F™ 기술 플랫폼으로 미국 특허 번호 12,357,584 B2를 획득했습니다. 해당 특허는 2038년 12월까지 유효하며, E. coli, MRSA, 인플루엔자, 라이노바이러스 및 M. tuberculosis를 포함한 다양한 병원체에 효과적인 항미생물 및 항바이러스 특성을 지닌 고유 조성물을 포괄합니다.
이 기술은 감염병 시장의 성장 수요를 겨냥하며, 해당 시장은 2024년 217억 달러에서 2023년 340억 달러로 확대될 것으로 예상되며 연평균 성장률(CAGR)은 5.77%입니다. 회사는 미국 및 전 세계에서 3F™ 기술의 상용화를 위해 파트너십을 적극적으로 모색하고 있습니다.
Impact Biomedical (IBO) a obtenu le brevet américain n° 12,357,584 B2 pour sa plateforme technologique 3F™, axée sur le contrôle des maladies infectieuses grâce à des fragrances fonctionnelles d'origine végétale. Le brevet, valable jusqu'en décembre 2038, couvre des compositions uniques aux propriétés antimicrobiennes et antivirales efficaces contre divers agents pathogènes, notamment E. coli, MRSA, la grippe, le rhinovirus et M. tuberculosis.
La technologie répond à la croissance du marché des maladies infectieuses, projeté pour passer de 21,7 milliards de dollars en 2024 à 34 milliards de dollars en 2023, avec un taux de croissance annualisé (CAGR) de 5,77 %. L'entreprise recherche activement des partenariats pour commercialiser la technologie 3F™ aux États-Unis et à l'échelle mondiale.
Impact Biomedical (IBO) hat das US-Patent Nr. 12.357.584 B2 für seine 3F™-Technologieplattform erhalten, die auf die Bekämpfung von Infektionskrankheiten durch pflanzenbasierte funktionelle Duftstoffe abzielt. Das Patent ist bis Dezember 2038 gültig und deckt einzigartige Zusammensetzungen mit antimikrobiellen und antiviralen Eigenschaften ab, die gegen verschiedene Erreger wie E. coli, MRSA, Influenza, Rhinovirus und M. tuberculosis wirksam sind.
Die Technologie spricht den wachsenden Markt für Infektionskrankheiten an, der voraussichtlich von $21.7B im Jahr 2024 auf $34B im Jahr 2023 anwächst, mit einer CAGR von 5,77%. Das Unternehmen sucht aktiv Partner, um die 3F™-Technologie in den USA und weltweit zu kommerzialisieren.
- Secured new US patent valid until December 2038, expanding intellectual property portfolio
- Technology shows potential effectiveness against multiple major pathogens including MRSA and tuberculosis
- Targeting growing infectious disease market projected to reach $34B by 2023
- Active discussions ongoing with potential commercial partners
- Product still requires development and commercialization before generating revenue
- Potential competition from existing infectious disease treatments
Insights
IBO secures US patent for 3F™ technology with broad antimicrobial applications, strengthening their IP portfolio until 2038.
Impact Biomedical has secured an important addition to their intellectual property portfolio with the issuance of US patent 12,357,584 B2 for their 3F™ technology platform. This patent, valid until December 7, 2038, covers compositions derived from plant fragrances with antimicrobial and antiviral properties, offering the company nearly 13 years of market exclusivity.
The technology's potential applications are particularly noteworthy—ranging from surface disinfectants to potential therapeutic treatments against significant pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis. This dual-use potential (both as disinfectant and therapeutic) substantially expands the technology's commercial applications.
This patent strengthens IBO's existing 3F™ intellectual property estate, which already includes related technologies for insect repellents and antimicrobial applications internationally. The timing is strategically valuable, as the infectious disease market is projected to grow from
While the company mentions ongoing discussions with potential partners, no specific commercialization timeline or partnership details were disclosed. The patent's broad claims covering both compositions and methods of use provide robust protection, but the pathway from patent to marketable product remains lengthy, particularly if therapeutic applications require clinical trials and regulatory approvals.
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform.
This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038.
This expands Impact Biomedical’s 3F™ patent estate which includes insect repellent compositions and anti-microbial applications in the United States and other countries. It also further demonstrates IBO’s commitment to discovering, developing, and patenting unique technologies to meet unmet needs in human healthcare.
These compositions and formulations have unique antimicrobial and antiviral properties. The compositions can be formulated to treat or limit the occurrence of various diseases and to kill and/or be used as a disinfectant against various microbes, pathogens, and the like.
Potential applications include killing microbes as a disinfectant and to be administered to a patient to treat an infectious disease condition. The composition has potential effectiveness against various pathogens including but not limited to E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, continue to pose significant global health challenges, driving demand for new offerings and solutions in both established and developing regions worldwide.
The worldwide infectious disease market is projected to grow from
Upon notification of the patent issue, IBO CEO Frank Heuszel said, “This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare. We continue discussions with potential partners to move 3F™ towards the market in the US and other countries worldwide.”
About IBO:
Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com
FAQ
What is Impact Biomedical's (IBO) new patent for?
When does Impact Biomedical's new 3F™ patent expire?
What pathogens can Impact Biomedical's 3F™ technology potentially treat?
What is the market size for infectious diseases that Impact Biomedical is targeting?
How does Impact Biomedical plan to commercialize its 3F™ technology?
